Back to Search
THOMAS BEER, M.D.
Anesthesiology Physician
NPI: 1376520437IndividualAccepts Medicare
Specialties, Licenses & Credentials
Anesthesiology PhysicianPrimary
Anesthesiology
Code: 207L00000X
A74347(CA)35058(AZ)
Education
UNIVERSITY OF COLORADO SCHOOL OF MEDICINE, DENVER
Class of 1999
Research & Publications (20)
Keloidal and granular cell change in a series of 171 atypical fibroxanthomas.
PMID 19656166·J Cutan Pathol·2010
8-other
Perineural invasion: identification, significance, and a standardized definition.
PMID 19215258·Dermatol Surg·2009
5-case
The association of bone mineral density with prostate cancer risk in the Osteoporotic Fractures in Men (MrOS) Study.
PMID 19124492·Cancer Epidemiol Biomarkers Prev·2009
4-observational
Prostate cancer-associated gene expression alterations determined from needle biopsies.
PMID 19366833·Clin Cancer Res·2009
4-observational
Merkel cell carcinomas with CK20 negative and CK7 positive immunostaining.
PMID 19220637·J Cutan Pathol·2009
8-other
Phase I study of ixabepilone, mitoxantrone, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy: a study of the department of defense prostate cancer clinical trials consortium.
PMID 19349545·J Clin Oncol·2009
8-other
Phase II study of calcitriol-enhanced docetaxel in patients with previously untreated metastatic or locally advanced pancreatic cancer.
PMID 18843448·Invest New Drugs·2009
3-trial
CD117 is not a useful marker for diagnosing atypical fibroxanthoma.
PMID 19652583·Am J Dermatopathol·2009
8-other
Department of Defense prostate cancer clinical trials consortium: a new instrument for prostate cancer clinical research.
PMID 19213669·Clin Genitourin Cancer·2009
8-other
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
PMID 19359544·Science·2009
3-trial
C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial.
PMID 18428198·Cancer·2008
4-observational
Vascular density has prognostic value in Merkel cell carcinoma.
PMID 18806485·Am J Dermatopathol·2008
8-other
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
Southwest Oncology Group phase II study of ispinesib in androgen-independent prostate cancer previously treated with taxanes.
PMID 18824433·Clin Genitourin Cancer·2008
3-trial
Mast cells have prognostic value in Merkel cell carcinoma.
PMID 18212540·Am J Dermatopathol·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1850 N CENTRAL AVE, STE 1600
PHOENIX, AZ 85004 - Phone
- (602) 744-4765
Quick Facts
- NPI
- 1376520437
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile